antirheumatics/obesity

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 52 rezilta yo

[Left and right ventricular diastolic dysfunction in patients with early rheumatoid arthritis before prescribing disease-modifying antirheumatic therapy].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To estimate the rate of diastolic dysfunction (DD) of the left and right ventricles (LV and RV) in patients with early rheumatoid arthritis (RA) before using disease-modifying antirheumatic drugs (DMARDs) therapy and to investigate its association with traditional risk factors (TRFs) for

Effects of overweight and underweight on the treatment outcomes of rheumatoid arthritis patients treated with biological drugs: A retrospective observational descriptive study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The effects of the body size condition (overweight and underweight) on the outcome of antirheumatic drugs are unclear. The aim of this study was to elucidate the relationship between body size and treatment outcomes in rheumatoid arthritis patients treated with biological antirheumatic

No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The aim of this study was to determine whether body mass index (BMI) is associated with clinical response to biologics in patients with rheumatoid arthritis (RA). We enrolled 68 patients with RA who were treated with biological disease-modifying antirheumatic drugs (bDMARDs). Biologics included

Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Obesity is implicated in rheumatoid arthritis (RA) development, severity, outcomes, and treatment response. We estimated the independent effects of overweight and obesity on ability to achieve sustained remission (sREM) in the 3 years following RA diagnosis. METHODS Data were from the

Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To investigate whether overweight/obesity at diagnosis affects the chances of decrease in disease activity and pain in early rheumatoid arthritis (RA). METHODS We investigated incident RA cases from the population-based Epidemiological Investigation of risk factors for Rheumatoid Arthritis

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The aim of our study was to investigate the influence of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and body mass index (BMI) on circulating drug levels and clinical response to tumour necrosis factor inhibitor (TNFi) therapy in axial spondyloarthritis

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Few studies have investigated the impact of obesity on the response to tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA). The aim of our study was to investigate the impact of different body mass index (BMI) categories on TNFi response in a large cohort of

Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND

Obesity is over-represented in patients with psoriatic arthritis (PsA) and associated with higher disease activity, poorer effect of treatment and increased cardiovascular morbidity. Studies on the effects of weight loss are however needed. This study aimed to

Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Obesity is a worldwide epidemic and a growing body of evidence suggests that it may affect the body's response to biologic agents. We investigated the influence of obesity on the efficacy of different biologic agents used to treat inflammatory diseases. METHODS Medline, EMBASE and the

The Influence of Overweight and Obesity on Treatment Response in Juvenile Idiopathic Arthritis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Background: There is evidence that obesity could be a risk factor for the severity and response to treatment in adult patients with rheumatoid arthritis (RA) due both to the mechanical effect of overweight and to the potential pro-inflammatory effects of cytokines produced by adipose tissue.

Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To determine the association of obesity, defined as a body mass index (BMI) ≥30 or ≥28 kg/m(2) or by waist circumference (WC), with disease activity and severity, as well as its relationship to comorbidities in rheumatoid arthritis (RA). METHODS The study population comprised 1,596

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti-tumor necrosis factor α

Obesity and its role in the management of rheumatoid and psoriatic arthritis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In the last decade, interest has been growing in the relationship between obesity and several other clinical conditions, besides the well-established links between body mass index (BMI) and cardiovascular diseases or cancer. A particular focus has been put on the impact of a higher BMI on

Obesity and Psoriatic Arthritis: A Narrative Review

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Patients with psoriatic arthritis (PsA) have a higher burden of cardio-metabolic comorbidities like obesity, hypertension, diabetes, and cardiovascular disease compared to the general population. Adipose tissue is thought to promote a chronic low grade inflammatory state through inflammatory

[Epidemiology of antirheumatic drug-induced ulcer in comparison with peptic gastroduodenal ulcer. Five-year analysis of a hospital patient sample].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Within the framework of a five-year analysis of a hospital population (n = 503), the epidemiological and diagnostic data of patients with non-steroidal anti-inflammatory drugs-associated ulcers of the stomach and duodenum (AIU) were evaluated and compared with those of patients with peptic ulcers

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye